Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Product PortfolioThe company isone of the largest and fastest-growing injectable-focused companies, providing 89+ product SKUs, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, across 15+ therapeutic areas.[1][2]The company launched 85 new molecules between FY22 and FY24, and introduced 12 new molecules, including Cetrorelix Acetate, Tranexamic Acid, Eribulin mesylate, Plerixafor, Nelarabine, etc., in the US market during H1 FY25.[3][4]
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1760.20 | 36.58 | 422330.94 | 0.91 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.43 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6642.50 | 70.96 | 176337.50 | 0.45 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 11.44 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 3936.80 | 61.50 | 133239.20 | 0.81 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 15.77 | 13.26 | 0.33 |
| 4. | Cipla | 1530.80 | 22.73 | 123653.62 | 0.85 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.76 | 14.72 | 0.01 |
| 5. | Dr Reddy's Labs | 1256.20 | 18.16 | 104846.27 | 0.64 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.91 | 12.95 | 0.16 |
| 6. | Lupin | 2149.70 | 22.71 | 98198.04 | 0.56 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 5.00 | 12.41 | 0.32 |
| 7. | Zydus Lifesci. | 931.05 | 18.63 | 93685.42 | 1.18 | 1238.60 | 40.92 | 6123.20 | 16.92 | 24.31 | 24493.90 | 31.10 | 5029.35 | 1283.60 | 3.70 | 14.64 | 0.38 |
| 8. | Gland Pharma | 1693.30 | 24.13 | 27898.20 | 1.06 | 302.00 | 7.20 | 1074.15 | 1.05 | 15.85 | 4154.12 | 36.57 | 1156.38 | 302.00 | 2.78 | 10.91 | 0.00 |
| – | Median: 151 Co. | 405.75 | 29.8 | 1679.94 | 0.11 | 12.57 | 10.46 | 152.64 | 10.58 | 15.06 | 574.01 | 15.93 | 43.84 | 13.49 | 3.11 | 8.64 | 0.22 |
Standalone figures in ₹ crores
| Dec 2022 | Dec 2023 | Dec 2024 | Jun 2023 | Jun 2024 | Jun 2025 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 926 | 1,098 | 1,011 | 884 | 1,012 | 1,039 | 785 | 1,175 | 1,030 | 1,048 | 1,011 | 1,063 | 1,074 |
Expenses | 642 | 728 | 620 | 625 | 718 | 680 | 616 | 742 | 636 | 753 | 664 | 699 | 699 |
Operating Profit | 284 | 369 | 391 | 259 | 294 | 359 | 169 | 433 | 394 | 295 | 347 | 364 | 375 |
Other Income | 62 | 43 | 65 | 35 | 48 | 55 | -18 | 47 | 44 | 66 | 41 | 58 | 83 |
Profit before tax | 305 | 372 | 394 | 254 | 300 | 362 | 112 | 433 | 391 | 322 | 347 | 380 | 409 |
Tax % | 25% | 26% | 25% | 26% | 26% | 26% | 29% | 26% | 26% | 26% | 26% | 26% | 26% |
Net Profit | 228 | 277 | 295 | 188 | 223 | 269 | 79 | 321 | 290 | 240 | 258 | 282 | 302 |
EPS in Rs | 13.82 | 16.81 | 17.91 | 11.39 | 13.53 | 16.34 | 4.81 | 19.51 | 17.60 | 14.55 | 15.64 | 17.10 | 18.33 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 991 | 994 | 1,348 | 1,479 | 1,620 | 2,044 | 2,633 | 3,463 | 4,401 | 3,617 | 4,167 | 4,116 | 4,154 |
Expenses | 630 | 678 | 845 | 854 | 1,085 | 1,338 | 1,678 | 2,161 | 2,890 | 2,598 | 2,758 | 2,674 | 2,635 |
Operating Profit | 361 | 316 | 502 | 625 | 535 | 706 | 955 | 1,302 | 1,511 | 1,019 | 1,410 | 1,443 | 1,519 |
Other Income | 9 | 30 | 37 | 34 | 49 | 66 | 139 | 135 | 224 | 184 | 166 | 215 | 246 |
Interest | 13 | 17 | 16 | 6 | 4 | 4 | 7 | 3 | 5 | 7 | 8 | 23 | 33 |
Depreciation | 28 | 57 | 63 | 74 | 78 | 82 | 95 | 99 | 110 | 147 | 162 | 169 | 175 |
Profit before tax | 327 | 272 | 459 | 578 | 502 | 686 | 993 | 1,335 | 1,619 | 1,048 | 1,405 | 1,466 | 1,557 |
Net Profit | 224 | 209 | 314 | 414 | 321 | 452 | 773 | 997 | 1,212 | 776 | 1,043 | 1,090 | 1,156 |
EPS in Rs | 190.40 | 133.53 | 202.40 | 267.01 | 207.24 | 291.65 | 49.88 | 60.94 | 73.78 | 47.11 | 63.34 | 66.14 | 70.18 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 32% | 27% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 16 | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Reserves | 822 | 1,379 | 1,662 | 2,074 | 2,395 | 2,847 | 3,631 | 5,887 | 7,142 | 7,937 | 8,979 | 9,739 | 10,034 |
Borrowings | 176 | 166 | 117 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | 5 | 4 |
Other Liabilities | 277 | 197 | 292 | 378 | 512 | 655 | 435 | 588 | 671 | 815 | 542 | 661 | 771 |
Total Liabilities | 1,287 | 1,758 | 2,086 | 2,474 | 2,928 | 3,523 | 4,086 | 6,496 | 7,834 | 8,773 | 9,541 | 10,422 | 10,825 |
Fixed Assets | 460 | 649 | 788 | 872 | 843 | 929 | 968 | 954 | 1,502 | 1,571 | 1,694 | 1,745 | 1,697 |
Gross Block | 565.31 | 820.49 | 1,020.22 | 1,005.52 | 1,054.45 | 1,219.58 | 1,347.81 | 1,430.70 | 2,081.32 | 2,294.96 | 2,579.91 | 2,798.04 | – |
Accumulated Depreciation | 105.57 | 171.86 | 232.34 | 133.94 | 211.81 | 290.83 | 379.71 | 476.47 | 579.13 | 724.41 | 886.18 | 1,053.05 | – |
CWIP | 208 | 192 | 202 | 161 | 199 | 123 | 188 | 338 | 191 | 177 | 120 | 42 | 53 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 163 | 8 | 2,386 | 2,790 | 3,293 |
Other Assets | 619 | 917 | 1,096 | 1,441 | 1,887 | 2,471 | 2,929 | 5,203 | 5,978 | 7,017 | 5,342 | 5,845 | 5,783 |
Total Assets | 1,287 | 1,758 | 2,086 | 2,474 | 2,928 | 3,523 | 4,086 | 6,496 | 7,834 | 8,773 | 9,541 | 10,422 | 10,825 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | – | – | 220 | 476 | 202 | 185 | 701 | 605 | 791 | 368 | 1,136 | 1,074 |
Cash from Investing Activity | – | – | -12 | -100 | -359 | -319 | -761 | -1,521 | -1,007 | 1,211 | -2,918 | 1,582 |
Cash from Financing Activity | – | – | -93 | -116 | -4 | -3 | -7 | 1,238 | 35 | 15 | -7 | -340 |
Net Cash Flow | – | – | 115 | 260 | -160 | -136 | -67 | 322 | -181 | 1,594 | -1,789 | 2,316 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 62 | 62 | 95 | 103 | 107 | 90 | 83 | 71 | 89 | 87 | 103 | 101 |
Inventory Days | 229 | 283 | 248 | 271 | 283 | 388 | 250 | 312 | 205 | 421 | 253 | 265 |
Days Payable | 74 | 58 | 60 | 136 | 161 | 190 | 82 | 97 | 80 | 128 | 56 | 81 |
Cash Conversion Cycle | 217 | 288 | 283 | 239 | 229 | 289 | 251 | 286 | 214 | 381 | 299 | 284 |
Working Capital Days | 100 | 141 | 155 | 154 | 185 | 191 | 161 | 169 | 168 | 241 | 224 | 249 |
ROCE % | 39% | 22% | 28% | 30% | 22% | 27% | 30% | 28% | 25% | 15% | 17% | 16% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2025
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Jan 2023
Nov 2022
Oct 2022
Jul 2022
May 2022
Jan 2022
Nov 2021
Sep 2021
Jul 2021
May 2021
Feb 2021
Dec 2020
Stock Analysis
Corporate Announcements
